US Stock MarketDetailed Quotes
NAMS NewAmsterdam Pharma
- 24.590
- +0.470+1.95%
Close Nov 11 16:00 ET
- 24.590
- 0.0000.00%
Post 20:02 ET
2.27BMarket Cap-11126P/E (TTM)
24.860High23.905Low543.57KVolume24.180Open24.120Pre Close13.28MTurnover1.53%Turnover RatioLossP/E (Static)92.39MShares26.35052wk High6.00P/B876.70MFloat Cap8.90052wk Low--Dividend TTM35.65MShs Float32.880Historical High--Div YieldTTM3.96%Amplitude5.633Historical Low24.439Avg Price1Lot Size
About NewAmsterdam Pharma Company
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
Company Profile
SymbolNAMS
Company NameNewAmsterdam Pharma
Listing DateFeb 8, 2021
Founded2022
CEODr. Michael Harvey Davidson, M.D.
MarketNASDAQ
Employees29
Fiscal Year Ends12-31
AddressGooimeer 2-35
CityNaarden
ProvinceNoord-Holland
CountryNetherlands (the)
Zip Code1411 DC
Phone31-35-206-29-71
Company Executives
-
Name
- Position
- Salary
-
Dr. Michael Harvey Davidson, M.D.
- Chief Executive Officer and Director
- 5.81M
-
Louise Kooij
- Chief Accounting Officer
- --
-
Dr. Johannes Jacob Pieter Kastelein, M.D.
- Chief Scientific Officer and Director
- 2.98M
-
Douglas F. Kling
- Chief Operating Officer
- --
-
Juliette Audet
- Chief Business Officer
- 45.63K
-
William B.J. Jones, Jr
- Chief Commercial Officer
- --
-
Ian Somaiya
- Chief Financial Officer
- 3.55M
-
Willian H Lewis
- Lead Independent Chairman of the Board
- --
-
William H. Lewis, J.D.,M.B.A.
- Chairman of the Board
- --
-
Dr. James N. Topper, M.D.,PhD
- Independent Director
- 40.00K
-
Janneke van der Kamp
- Independent Director
- 134.66K
-
Louis G. Lange, M.D.
- Independent Director
- 339.05K
-
Dr. Nicholas S. Downing, M.D.
- Independent Director
- 47.33K
-
Wouter Joustra
- Independent Director
- --
-
Mark C. McKenna
- Independent Director
- --
-
John W. Smither
- Independent Director
- 138.83K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data